http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Underlying representation in geminates: from OT perspective
Sung-Hoon Hong,Chang-Kook Suh 한국음운론학회 2004 음성·음운·형태론 연구 Vol.10 No.1
Hong, Sung-Hoon, and Chang-Kook Suh. 2004. Underlying represen-tation in Geminates: from an OT perspective. Studies in Phonetics, Phonology and Morphology. 10.1. 129.144. This research has examined the status of Underlying Representation (UR) in Optimality Theory focusing on the representation of consonant geminates. For this purpose, we have examined geminate/singleton alternation in Ponapean employing Lexicon Optimization (LO), an algorithm proposed to select a UR among multiple inputs. We have seen that simple application of LO is problematic in singling out a UR for the case of alternation. This leads us to the version of LO that is performed on the paradigms, rather than on an individual forms (Tesar and Smolensky 1996, 2000, Inkelas 1995, 1998). After a thorough implementation of LO, we have found that the URs are simply identical to the input forms; geminate UR for the alternating case and singleton UR for the nonalternating case. Further, it was shown that a unique underlying representation of geminates, regardless of their positions in which they occur, can account for the exceptional geminate behaviors. (Hansung University and Cheonan University)
Seong Hoon Kim,Ji Hoon Kim,Jae Hoon Lee,Dong‑Woo Suh,Jae Sang Lee 대한금속·재료학회 2022 METALS AND MATERIALS International Vol.28 No.9
Prediction of retained austenite fraction is quite important in designing advanced high strength steels since retained austeniteis the source of transformation-induced plasticity. The present study investigates the phase constitution of a medium-carbonQ&P steel by comparing various approaches to the transformation stasis of bainitic ferrite and applying them to the partitioningprocess. Among them, the modified GEB approach gave the best agreement with the experimental observation, includingthe effects of heat-treatment condition and chemical composition on phase constitution. This indicates phase transformationduring partitioning can be effectively described by the physics of Gibbs energy balance approach.
Sung Woo Kwon,Sang-Don Park,Jeonggeun Moon,Pyung Chun Oh,Ho-Jun Jang,Hyun Woo Park,Tae-Hoon Kim,Kyounghoon Lee,Jon Suh,WoongChol Kang 대한심장학회 2018 Korean Circulation Journal Vol.48 No.11
Background and Objectives: We aimed to compare outcomes of complete revascularization (CR) versus culprit-only revascularization for ST-segment elevation myocardial infarction(STEMI) and multivessel disease (MVD) in the 2nd generation drug-eluting stent (DES) era. Methods: From 2009 to 2014, patients with STEMI and MVD, who underwent primary percutaneous coronary intervention (PCI) using a 2nd generation DES for culprit lesions were enrolled. CR was defined as PCI for a non-infarct-related artery during the index admission. Major adverse cardiovascular event (MACE) was defined as cardiovascular (CV) death, non-fatal myocardial infarction, target lesion revascularization, or heart failure during the follow-up year. Results: In total, 705 MVD patients were suitable for the analysis, of whom 286 (41%) underwent culprit-only PCI and 419 (59%) underwent CR during the index admission. The incidence of MACE was 11.5% in the CR group versus 18.5% in the culprit-only group (hazard ratio [HR], 0.56; 95% confidence interval [CI], 0.37–0.86; p<0.01; adjusted HR, 0.64; 95% CI, 0.40–0.99; p=0.04). The CR group revealed a significantly lower incidence of CV death (7.2% vs. 12.9%; HR, 0.51; 95% CI, 0.31–0.86; p=0.01 and adjusted HR, 0.57; 95% CI; 0.32–0.97; p=0.03, respectively). Conclusions: CR was associated with better outcomes including reductions in MACE and CV death at 1 year of follow-up compared with culprit-only PCI in the 2nd generation DES era.
Sung-Hwan Suh,권혁찬,Ji-Hoon Jo,Young-Rak Cho,Bong-Gun Seo,Dong-Mee Lee,Sung-Hyun Kim,Jae-Seok Kim,김효진 대한암학회 2005 Cancer Research and Treatment Vol.37 No.5
Purpose: To determine the activity and the toxicity associated with a low dose regimen of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every two weeks (modified FOLFOX 4) as a salvage therapy for advanced gastric cancer patients.Materials and Methods: Between December 2003 and December 2004, 33 patients were enrolled in this study. The patients were treated with oxaliplatin 85 mg/m2 as a 2-hour infusion on the first day plus LV 20 mg/m2 over 10 minutes. Subsequently, the patients were given a 5-FU bolus 400 mg/m2 followed by a 22-hour continuous infusion of 600 mg/m2 on days 1∼2. The treatment was repeated at 2 week intervals.Results: The median age of the patients was 50 years (range: 31∼74), 82% (27/33) had the Eastern Cooperative Oncology Group performance status was 0 and 1. Of the30 patients who could be evaluated for their tumor response, 8 achieved a partial response, with an overall response rate of 26.7% (95% confidence interval (CI): 20.5∼32.7%). Fifteen patients (50%) showed stable disease and 7 patients (23.3%) progressed during the course of treatment. The median time from the start of chemotherapy to progression was 3.5 months (95% CI: 2.6∼4.4 months) and the median overall survival time was 7.9 months (95% CI: 5.9∼9.9 months). The major grade 3/4 hematological toxicity encountered included neutropenia (45.4%) and thrombocytopenia (3.0%). Neutropenic feveroccurred during only 2 of the 178 cycles. The most com - mon non-hematological toxicity encountered was grade 1/2 nausea/vomiting, which occurred in 18.2% of patients, diarrhea in 12.1% and neuropathy in 15.2%. There were no treatment related deaths.Conclusion: The modified FOLFOX 4 regimen appears to be a safe and effective salvage therapy for advanced gastric cancer patients. Purpose: To determine the activity and the toxicity associated with a low dose regimen of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every two weeks (modified FOLFOX 4) as a salvage therapy for advanced gastric cancer patients.Materials and Methods: Between December 2003 and December 2004, 33 patients were enrolled in this study. The patients were treated with oxaliplatin 85 mg/m2 as a 2-hour infusion on the first day plus LV 20 mg/m2 over 10 minutes. Subsequently, the patients were given a 5-FU bolus 400 mg/m2 followed by a 22-hour continuous infusion of 600 mg/m2 on days 1∼2. The treatment was repeated at 2 week intervals.Results: The median age of the patients was 50 years (range: 31∼74), 82% (27/33) had the Eastern Cooperative Oncology Group performance status was 0 and 1. Of the 30 patients who could be evaluated for their tumor response, 8 achieved a partial response, with an overall response rate of 26.7% (95% confidence interval (CI): 20.5 ∼32.7%). Fifteen patients (50%) showed stable disease and 7 patients (23.3%) progressed during the course of treatment. The median time from the start of chemotherapy to progression was 3.5 months (95% CI: 2.6∼4.4 months) and the median overall survival time was 7.9 months (95% CI: 5.9∼9.9 months). The major grade 3/4 hematological toxicity encountered included neutropenia (45.4%) and thrombocytopenia (3.0%). Neutropenic fever occurred during only 2 of the 178 cycles. The most com - mon non-hematological toxicity encountered was grade 1/2 nausea/vomiting, which occurred in 18.2% of patients, diarrhea in 12.1% and neuropathy in 15.2%. There were no treatment related deaths.Conclusion: The modified FOLFOX 4 regimen appears to be a safe and effective salvage therapy for advanced gastric cancer patients.
Suh, Guk-Hee,Jung, Hee Yeon,Lee, Chang Uk,Oh, Byoung Hoon,Lee, Sang-Kyu,Lee, NamJin,Kim, JaeHyun,Kee, Baik Seok,Ko, Daekwan,Kim, Young-Hoon,Ju, Young-Su,Hong, InJa,Choi, Sungku S. Karger AG 2005 DEMENTIA AND GERIATRIC COGNITIVE DISORDERS Vol.21 No.1
<P><I>Objective:</I> To investigate the effect of the apolipoprotein E (ApoE) ε4 allele on the efficacy and tolerability of galantamine treatment. <I>Methods:</I> A total of 202 patients with mild to moderate Alzheimer’s disease participated in a 16-week, prospective, multi-center, randomized, double-blind galantamine trial in a Korean population. Patients were assessed at baseline and after 4, 8 and 16 weeks of randomized treatment using the 11-item cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog/11), the Clinician’s Interview-Based Impression of Change plus Caregiver Input (CIBIC-plus), the Disability Assessment for Dementia Scale (DAD), the Behavioural Pathology in Alzheimer’s Disease Rating Scale (BEHAVE-AD) and adverse events. ApoE genotypes were determined for all subjects. <I>Results:</I> Of the 202 subjects, 115 carried at least one ApoE ε4 allele and 87 did not. In both ApoE ε4 carriers and ApoE ε4 noncarriers, significant improvements were detected relative to baseline on ADAS-cog/11, CIBIC-plus, DAD and BEHAVE-AD. ApoE ε4 noncarriers showed better improvement in mean total BEHAVE-AD score and mean psychosis (delusions and hallucinations) subscale score than ApoE ε4 carriers. The incidence of weight loss was significantly higher in ApoE ε4 carriers (n = 11; 9.6%) than in ApoE ε4 noncarriers (n = 1; 1.2%) during this 16-week study, even though 92% of patients who complained of weight loss completed this 16-week trial successfully. <I>Conclusion:</I> ApoE ε4 genotype does not affect galantamine-related improvements in cognition, global rating, function and behavior. Longer prospective studies with larger patient populations are required to confirm these new findings.</P><P>Copyright © 2006 S. Karger AG, Basel</P>
( Sang Jung Park ),( Yong Kwon Kim ),( Yeon Seok Seo ),( Seung Woon Park ),( Han Ah Lee ),( Tae Hyung Kim ),( Sang Jun Suh ),( Young Kul Jung ),( Ji Hoon Kim ),( Hyunggin An ),( Hyung Joon Yim ),( Jae 대한간학회 2016 Clinical and Molecular Hepatology(대한간학회지) Vol.22 No.4
Background/Aims: Practice guidelines recommend endoscopic band ligation (EBL) and endoscopic variceal obturation (EVO) for bleeding from esophageal varices and fundal varices, respectively. However, the optimal treatment for bleeding from cardiac varices along the lesser curvature of the stomach (GOV1) remains undefined. This retrospective study compared the efficacy between EBL and EVO for bleeding from GOV1. Methods: Patients treated by EBL or EVO via cyanoacrylate injection for bleeding from GOV1 were enrolled. Patients diagnosed with hepatocellular carcinoma or treated with endoscopic injection sclerotherapy were excluded. Results: The study included 91 patients treated for bleeding from GOV1. The mean age was 56.3±10.9 years (mean±SD), and 78 of them (85.7%) were men. Overall, 51 and 40 patients were treated with EBL and EVO, respectively. A trend for a higher hemostasis rate was noted in the EVO group (100%) than in the EBL group (82.6%, P=0.078). Varices rebled in 15 patients during follow-up. The rebleeding rate was significantly higher in the EBL group than in the EVO group (P=0.004). During follow-up, 13 patients died (11 in the EBL group and 2 in the EVO group); the survival rate was marginally significant between two groups (P=0.050). The rebleeding-free survival rate was significantly higher in the EVO group than in the EBL group (P=0.001). Conclusions: Compared to EBL, EVO offered significantly lower rebleeding rates, significantly higher rebleeding-free survival rates, and a trend for higher hemostasis and survival rates. EVO appears to be the better therapeutic option for bleeding from GOV1. (Clin Mol Hepatol 2016;22:487-494)